Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Moussalli

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Journal of the National Cancer Institute|May 14, 2009
Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesisXiangsheng Zuo, Zhanglong Peng, Micheline J Moussalli, et al.
Gastroenterology|January 29, 1999
Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc GroupR Sobesky, P Mathurin, F Charlotte, et al.
Journal of Viral Hepatitis|February 16, 2006
A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markersC d'Arondel, M Munteanu, J Moussalli, et al.
Transplantation|October 1, 1991
Chronic liver dysfunction in heart transplant recipients, with special reference to viral B, C, and non-A, non-B, non-C hepatitis. A retrospective study in 80 patients with follow-up of 60 monthsJ F Cadranel, P Grippon, F Lunel, et al.
Gastroenterologie Clinique Et Biologique|July 31, 2009
Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trialsT Poynard, J Massard, M Rudler, et al.
Acta Gastro-Enterologica Belgica|January 29, 1999
Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologieT Poynard, J Moussalli, V Ratziu, et al.
Journal of Hepatology|July 29, 1999
A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, FranceS Pol, P Couzigou, M Bourlière, et al.
Journal of Viral Hepatitis|June 26, 2002
Fatigue in patients with chronic hepatitis CT Poynard, P Cacoub, V Ratziu, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 26, 2015
15-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL-6/STAT3 signaling pathwayFei Mao, Min Xu, Xiangsheng Zuo, et al.
Gastroenterologie Clinique Et Biologique|December 17, 2008
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 updateT Poynard, M Muntenau, R Morra, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Journal of the National Cancer Institute|May 14, 2009
Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesisXiangsheng Zuo, Zhanglong Peng, Micheline J Moussalli, et al.
Gastroenterology|January 29, 1999
Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc GroupR Sobesky, P Mathurin, F Charlotte, et al.
Journal of Viral Hepatitis|February 16, 2006
A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markersC d'Arondel, M Munteanu, J Moussalli, et al.
Transplantation|October 1, 1991
Chronic liver dysfunction in heart transplant recipients, with special reference to viral B, C, and non-A, non-B, non-C hepatitis. A retrospective study in 80 patients with follow-up of 60 monthsJ F Cadranel, P Grippon, F Lunel, et al.
Gastroenterologie Clinique Et Biologique|July 31, 2009
Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trialsT Poynard, J Massard, M Rudler, et al.
Acta Gastro-Enterologica Belgica|January 29, 1999
Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologieT Poynard, J Moussalli, V Ratziu, et al.
Journal of Hepatology|July 29, 1999
A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, FranceS Pol, P Couzigou, M Bourlière, et al.
Journal of Viral Hepatitis|June 26, 2002
Fatigue in patients with chronic hepatitis CT Poynard, P Cacoub, V Ratziu, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 26, 2015
15-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL-6/STAT3 signaling pathwayFei Mao, Min Xu, Xiangsheng Zuo, et al.
Gastroenterologie Clinique Et Biologique|December 17, 2008
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 updateT Poynard, M Muntenau, R Morra, et al.
Pageof 4